Masimo (NASDAQ:MASI – Get Free Report)‘s stock had its “hold” rating reaffirmed by equities research analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...

Our mission is to improve life, improve patient outcomes; and reduce the cost of care. Masimo SET ® Measure-through Motion and Low Perfusion ™ pulse oximetry, introduced in 1995, has been shown in ...

After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...

Today the Board of Directors (the “Board”) of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointe ...

Piper Sandler analyst Jason Bednar maintained a Buy rating on Masimo (MASI – Research Report) today and set a price target of $210.00. The ...

BTIG analyst Marie Thibault reiterated a Buy rating on Masimo (MASI – Research Report) today and set a price target of $178.00. The company’s ...

Masimo Corp. today announced Katie Szyman as its new chief executive, effective Feb. 12. Szyman is currently worldwide ...

Interim CEO Michelle Brennan, who was backed by the activist investor, was appointed chairman of Masimo's board, and Politan founder Quentin Koffey was named the vice-chairman. The new ...

"Katie’s more than 35 years of relevant experience and her unique mix of expertise set her apart during our search and make her an ideal fit to lead the next innovation-focused stage of Masimo ...